Tango Therapeutics · 2 weeks ago
Vice President, Safety and Pharmacovigilance
Boston, MA
Part-time
Onsite
Director/Executive
$311K/yr - $467K/yr
10+ years expTango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. They are seeking an innovative and collaborative leader to serve as Vice President, Safety and Pharmacovigilance, who will provide strategic direction and leadership for the Medical Safety Science function and manage the Pharmacovigilance team.
BiotechnologyHealth CareMedicalTherapeutics
Responsibilities
Lead and oversee all pharmacovigilance and risk management activities for Tango’s clinical programs
Develop and execute comprehensive safety science strategies for oncology drug development programs from preclinical through post-market surveillance
Provide safety expertise and risk-benefit assessments to support go/no-go decisions for oncology programs
Represent Tango in interactions with health authorities, including preparing and presenting safety data in regulatory meetings
Provide medical safety expertise and leadership across all clinical development activities, including protocols, CSRs, IBs, ICFs, and regulatory briefing books
Oversee signal detection, safety surveillance, and benefit-risk assessments, implementing risk mitigation strategies as needed
Direct the preparation and review of key safety documents, including DSURs, SUSARs, periodic and annual safety reports, and regulatory communications
Develop and manage PV budgets, ensuring alignment with corporate objectives
Oversee the development and execution of safety processes, standards, and technologies to improve efficiency, scalability, and scientific quality
Direct the preparation of safety sections for regulatory submissions including INDs, NDAs, BLAs, and periodic safety reports
Oversee the development of safety monitoring plans and data safety monitoring boards for clinical trials
Build and lead a high-performing global safety science organization
Lead cross-functional safety teams and collaborate with clinical development, regulatory affairs, medical affairs, and commercial teams
Mentor and develop safety professionals, fostering a culture of scientific rigor and patient focus
Represent the company at regulatory meetings, scientific conferences, and industry forums
Collaborate with external partners including CROs, academic institutions, and regulatory consultants
Champion patient safety as a core organizational value
Qualification
Required
MD and 10+ years of experience in pharmacovigilance, safety science, or related roles within the pharmaceutical/biotech industry
Deep understanding of oncology drug development, including novel therapies (immunotherapy, targeted therapy, cell therapy)
Strong strategic thinking and business acumen
Excellent communication skills with ability to present complex safety data to various stakeholders
Expertise in global pharmacovigilance regulations, safety surveillance, reporting, and risk management strategies
Experience with regulatory authority interactions, safety database applications, and safety signal detection methodologies
Strong leadership skills with a proven track record of building and managing safety teams
Effective communicator with excellent written, verbal, and presentation skills
Ability to thrive in a fast-paced, high-growth environment, balancing multiple priorities while maintaining a strong commitment to ethical standards
Company
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
51-200 employees
H1B Sponsorship
Tango Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (1)
2024 (2)
2023 (1)
2022 (2)
2021 (1)
2020 (3)
Funding
Current Stage
Public CompanyTotal Funding
$548MKey Investors
Nextech InvestBoxer CapitalCasdin Capital
2025-10-23Post Ipo Equity· $197M
2021-08-11Post Ipo Equity· $186M
2021-08-11IPO
Leadership Team
Barbara Weber
President and CEO
Jannik N. Andersen
Chief Scientific Officer
Recent News
2026-01-11
2026-01-09
Company data provided by crunchbase